Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens for cataracts: how happy are patients after surgery?

NCT ID NCT06250322

Knowledge-focused Sponsor: Johnson & Johnson Surgical Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 307 cataract patients who received a special lens called TECNIS PC IOL to correct both cataracts and presbyopia (age-related blurry near vision). Researchers collected information from medical records and questionnaires to see how well patients saw, how satisfied they were, and what surgeons thought. The goal was to gather real-world data on the lens's performance after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TECNIS presbyopia-correcting intraocular lens
What this could lead to
If successful, this study could confirm that the TECNIS IOL provides good visual outcomes and high patient satisfaction after cataract surgery.
What could go wrong
This is an observational study with no control group, so results may not prove the lens is better than other options. It only looks at existing medical records, so data quality may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

307 people

The number who actually took part.

Started

Apr 2024

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A pre-existing population of subjects bilaterally implanted with the PC IOL at approximately 20 sites in Europe and Asia Pacific. Bilateral pseudophakic subjects implanted with the TECNIS PC IOL will be enrolled.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are bilaterally implanted with TECNIS PC IOL and are at least 45 days postoperative from their second eye surgery * Clear intraocular media * Signed informed consent and data protection documentation * Availability, willingness, ability, and sufficient cognitive awareness to comply with examination procedures * Ability to understand, read, and write English or the local language in which the informed consent and questionnaires are provided Exclusion Criteria: * Subjects with ongoing adverse events that might impact outcomes during the study * Use of systemic or ocular medication that may affect vision * Acute or chronic disease or condition, ocular trauma or surgery that may confound results * Patients with amblyopia, strabismus, nystagmus * Concurrent participation in another clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataracts are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataracts

Contacts and locations

Locations

  • All India Institute of Medical Sciences (AIIMS)

    New Delhi, India

  • Augenklinik Ahaus GmbH & Co. KG

    Ahaus, 48683, Germany

  • Augenklinik Dardenne

    Bonn, 53177, Germany

  • CHU Morvan Brest

    Brest, 29609, France

  • Centre for Sight Eye Institute

    New Delhi, 110029, India

  • Clinica Oftalmologica Diez del Corral

    Madrid, 28016, Spain

  • Clinique Juge Marseille

    Marseille, 13008, France

  • ETZ

    Tilburg, 5022 GC, Netherlands

  • Kim's eye clinic

    Seoul, 7301, South Korea

  • Korea Uni.Kuro

    Seoul, 8308, South Korea

  • Lions Eye Institute

    Nedlands, Western Australia, 6009, Australia

  • Mirzana IOA

    Madrid, 28035, Spain

  • Narayana Nethralaya

    Bengaluru, India

  • Oogziekenhuis Rotterdam

    Rotterdam, 3011 BH, Netherlands

  • Sunshine Eye Clinic

    Birtinya, Queensland, 4575, Australia

  • The Eye Foundation

    Coimbatore, India

  • The Queensland Eye Institute Foundation

    Woolloongabba, Queensland, 4102, Australia

  • Vienna Institute for Research in Ocular Surgery - A Karl-Landsteiner-Institute

    Vienna, 1140, Austria

  • Vision Eye Institute

    Chatswood, New South Wales, 2067, Australia

  • Vithas Alicante

    Madrid, 28043, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.